News
First TransNational Access Call to ERINHA’s full catalogue of services, including access to cutting edge high containment facilities was launched today!
The call is funded under the EU H2020 ERINHA-Advance project.
The following pathogens are prioritized:
- Ebola virus
- Marburg virus
- Lassa virus
- Crimean Congo Hemorrhagic Fever virus
- Nipah virus
A Memorandum of Understanding was signed on September 19, 2019 between ERINHA AISBL and European Vaccine Initiative, coordinator of TRANSVAC2 project.TRANSVAC2 (the European Network of Vaccine Research and Development) supports innovation for both prophylactic and therapeutic vaccine development and aims to establish a sustainable vaccine development infrastructure in Europe.
By signing the MoU, EVI and ERINHA intend to collaborate and join their efforts to accelerate the vaccine development research in the field of infectious diseases through strategic planning and programming the activities, alignment of calls for services and exchange of information.
The first step of the collaboration will be a simultaneous launch of Trans-National Access calls for both initiatives on 15th of October 2019.19 September, 2019
A Memorandum of Understanding was signed on September 19, 2019 between ERINHA AISBL and European Vaccine Initiative, coordinator of TRANSVAC2 project. TRANSVAC2 (the European Network of Vaccine Research and Development) supports innovation for both prophylactic and therapeutic vaccine development and aims to establish a sustainable vaccine development infrastructure in Europe.
By signing the MoU, EVI and ERINHA intend to collaborate and join their efforts to accelerate the vaccine development research in the field of infectious diseases through strategic planning and programming the activities, alignment of calls for services and exchange of information.
The first step of the collaboration will be a simultaneous launch of Trans-National Access calls for both initiatives on 15th of October 2019.
National Biosafety Laboratory participates in the Congress with several lectures:
Judit HENCZKÓ et al. Whole-genome sequencing of Burkholderia pseudomallei isolate in Hungary
Nóra Magyar et al. Revealing the different adaptation mechanism and genetic variations of the Crimean-Congo hemorrhagic fever virus using next generation sequencing
Bernadett PÁLYI et al. Road from infection to long-term shedding: Ebola virus isolation from human bodily fluidsKata HORVÁTI et al. Tailoring host cell specific delivery and bioavailability of antimycobacterial compounds
Kata HORVÁTI et al. Mycobacterium tuberculosis related T-cell epitope peptide-based vaccine candidates
Bernadett PÁLYI et al. A new possibility to unlock the innovation potential to risk group 4 pathogens research: Role of the European Research Infrastructure on Highly Pathogenic Agent (ERINHA) and the National Biosafety Laboratory
